News from Prosonix A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Sep 11, 2014, 04:00 ET Prosonix Confirms the Potential of its Multi-Component Particle™ Technology for Developing Novel Inhaled Dual and Triple Combination Therapies for Respiratory Diseases $countyNameToPathMap.put("sp

Successful Completion of Biomedical Catalyst Programme  Prosonix, an innovative speciality pharmaceutical company developing a portfolio of...


Sep 02, 2014, 04:00 ET Prosonix' Marketing Authorisation Application for PSX1001 - a Generic Version of GlaxoSmithKline's Flixotide® Evohaler® - Under Assessment in EU $countyNameToPathMap.put("sp

Triggers milestone payment from Mylan  Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled...


May 15, 2014, 04:00 ET Prosonix to Present Results of Phase 2 Clinical Study of PSX1002 in Chronic Obstructive Pulmonary Disease (COPD) at the American Thoracic Society Meeting $countyNameToPathMap.put("sp

First full presentation of data from randomised clinical study of glycopyrronium bromide made using Prosonix' novel particle-engineering...


Aug 16, 2013, 04:00 ET Final Patient Completes Prosonix' Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) $countyNameToPathMap.put("sp

PSX1002 is a novel, orally inhaled, drug-only, pMDI suspension formulation of glycopyrronium bromide, a long-acting muscarinic antagonist...


Jul 01, 2013, 04:00 ET Prosonix Appoints Frank Condella as Non-executive Director $countyNameToPathMap.put("sp

Brings further international experience in the development and commercialisation of respiratory medicines Prosonix, an innovative speciality...


May 22, 2013, 02:00 ET Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) $countyNameToPathMap.put("sp

First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle...


Jul 05, 2012, 04:00 ET Prosonix Enters Collaboration With Imperial College London to Accelerate Development of Engineered Combination Respiratory Medicines (Multi-component Particles™, MCPs™) $countyNameToPathMap.put("sp

Prosonix (Oxford, UK) announced that it has signed a Collaborative Research Agreement with Imperial College London to accelerate the development...